Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376593 | 0.87 | GABRA1 (0.53) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL17527230 | 0.85 | ALOX5 (0.48) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL3782409 | 0.85 | CA2 (0.47) | ATMKDM4EALDH1A1CYP19A1TSHR | |
| SCHEMBL30147378 | 0.85 | CA2 (0.47) | ATMKDM4EALDH1A1CYP19A1TSHR | |
| SCHEMBL11842974 | 0.83 | CA2 (0.61) | ATMALDH1A1POLBTSHRMAPK1 | |
| SCHEMBL2563443 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL465047 | 0.82 | GABRA1 (0.49) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL465088 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL16638886 | 0.82 | KDM4E (0.53) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL27002044 | 0.81 | KDM4E (0.61) | ATMKDM4ECYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107253903-B | Process for preparing a compound capable of binding to the S1P receptor and intermediates thereof | 北京海步医药科技股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-2592066-B1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2371811-B1 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8575134-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2592066-A1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-1826197-B1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.